Shares of AC Immune SA (NASDAQ:ACIU - Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.68 and traded as low as $2.31. AC Immune shares last traded at $2.35, with a volume of 150,985 shares trading hands.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of AC Immune in a report on Friday, November 15th.
View Our Latest Stock Report on ACIU
AC Immune Stock Performance
The company has a market cap of $238.45 million, a price-to-earnings ratio of -5.24 and a beta of 1.30. The firm's 50-day moving average price is $2.66 and its 200 day moving average price is $3.01.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Quinn Opportunity Partners LLC acquired a new position in AC Immune during the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP bought a new position in AC Immune in the fourth quarter valued at approximately $36,000. Boothbay Fund Management LLC bought a new position in AC Immune in the fourth quarter valued at approximately $38,000. RPO LLC bought a new position in AC Immune in the fourth quarter valued at approximately $51,000. Finally, Jane Street Group LLC bought a new position in AC Immune in the fourth quarter valued at approximately $66,000. Institutional investors and hedge funds own 51.36% of the company's stock.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
